Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of phencyclidine (
PCP
) on the dynamics of brain histamine (HA) were examined in the mouse brain.
PCP
(2-10 mg/kg i.p.) dose-dependently elevated the level of tele-methylhistamine (t-MH), a predominant metabolite of brain HA, without altering the HA level.
PCP
also enhanced the accumulation of t-MH after administration of pargyline hydrochloride (80 mg/kg i.p.).
PCP
at 5 mg/kg facilitated the HA depletion produced by (S)-alpha-fluoromethylhistidine markedly (50 mg/kg i.v.), a specific inhibitor of histidine decarboxylase.
Metoprine
(10 mg/kg i.p.), an inhibitor of HA-N-methyltransferase, decreased the t-MH level and increased the HA level. In the metoprine-treated mice,
PCP
at 10 mg/kg had no significant effect on the t-MH level, whereas it significantly increased the HA level. The increase in the t-MH level after administration of
PCP
(5 mg/kg) was observed in various brain regions except the pons-medulla oblongata. These results suggest that, in mice,
PCP
increases the brain HA turn-over possibly by facilitating the release of HA.
...
PMID:Phencyclidine and the dynamics of mouse brain histamine. 407 33
